LDLR and metabolic dysfunction-associated steatotic liver disease: Of the remaining patients, 308 (27%) of them showed a metabolomic phenotype similar to that of the Ldlr-KO/HFD mouse model and were classified as subtype C, and the rest of the NAFLD patients 305 (26%) were grouped together as subtype B [83].